Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
CLH enters its October 28 earnings date with the most bullish options positioning in months, a stock that has quietly pulled back from its highs, and a Street that remains constructive after a wave of target upgrades following the last print.
The clearest shift this week is in options. Put/call ratio has dropped to 0.52, well below the 20-day average of 1.86 and near the 52-week low of 0.21. That average is heavily distorted by a sustained period of extreme put-buying in August and early September, when the PCR ran above 6.0 for several weeks. That overhang has now cleared almost entirely. The current reading marks one of the most call-heavy setups CLH has seen all year, suggesting investors are positioning for upside into the print rather than hedging against a miss.
Short interest is a minor subplot, not a primary driver. At just over 2% of the free float, about 1.1 million shares, it is low by any measure and has risen only modestly, up around 2.7% on the week. The borrow market is entirely relaxed. Availability is effectively unlimited, with over 52 million shares available to lend, and cost to borrow runs at 0.37%, which is close to stock-loan floor pricing. There is no short-side pressure worth monitoring here.
The Street is broadly constructive, though not uniformly so. Most of the recent activity clustered around the July 29 print, when several firms raised targets after CLH beat expectations and the stock jumped 4.4% the following day. Citigroup lifted its Buy target to $376, TD Cowen raised to $380 and Needham went to $390. Barclays, the most recent mover, raised its target this week from $325 to $335 while staying at Equal-Weight, a sign that even the sceptics acknowledge the stock has moved. The consensus mean target of $360 implies around 13% upside from the current price of $316.93. Factor scores tilt in CLH's favour: analyst recommendation differential ranks in the 94th percentile of the universe, and EPS surprise ranks in the 82nd percentile, reflecting a company that has repeatedly beaten estimates. The weak spot is valuation. EV/EBITDA of 13.4x and a P/E near 31.8x are not stretched relative to industrial peers, but the EV/EBIT score ranks in the 13th percentile, a reminder that the stock prices in a good deal of the growth story already.
The bull case centres on PFAS-related emergency response work and M&A optionality from a strong balance sheet. The bear case is narrower: softness in the Safety-Kleen re-refined oil business remains a drag, and the stock's 13% pullback from earlier highs may reflect some re-rating of that segment's near-term profitability. Founder Alan McKim holds around 4.3% of shares as executive chair, and the recent insider register is dominated by tax-withholding transactions rather than discretionary sales, a compensation-mechanics footnote rather than a signal of concern. BlackRock added 273,000 shares in the latest quarter to reach 9.6%, and Geode added 183,000 shares, both passive flows consistent with index-weight adjustments rather than a change of view.
On the ownership side, one filing is worth noting. Wellington Management disclosed a 13G/A in May showing its stake had fallen from 9.7% to 6.8%. D1 Capital Partners similarly dropped from 5.2% to 2.5%, falling below the disclosure threshold. Both moves are as-last-disclosed: stakes around the 5% threshold can continue shifting without triggering new filings. The direction of travel, two meaningful holders trimming, is worth keeping in mind as the earnings date approaches.
The next eighteen days set up as a watch on two questions: whether the Safety-Kleen segment shows any sign of the base-oil price improvement the bulls expect, and whether the PFAS emergency response revenue that drove the last beat has held up through the third quarter. The PCR collapse from above 6.0 to below 0.55 in just three weeks is an unusually sharp rotation in options sentiment, and it means that the options market is now squarely positioned for a repeat of the July outcome rather than bracing for disappointment.
See the live data behind this article on ORTEX.
Open CLH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
